Adverse Drug Reaction News and Research

RSS
Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

Faldaprevir+ achieves viral cure in 88% of treatment-naïve genotype-1 hepatitis C patients in Asia

Faldaprevir+ achieves viral cure in 88% of treatment-naïve genotype-1 hepatitis C patients in Asia

EMRs emerge as valuable resource for detecting bad drug reactions

EMRs emerge as valuable resource for detecting bad drug reactions

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

COPD phase III study by Almirall and Forest Laboratories announces positive results

COPD phase III study by Almirall and Forest Laboratories announces positive results

MedeAnalytics' Accountable Care Solution selected for Mississippi's MEHRS application

MedeAnalytics' Accountable Care Solution selected for Mississippi's MEHRS application

LabCorp launches expanded IBD testing profile

LabCorp launches expanded IBD testing profile

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Bisphosphonate link to nonhealing fractures strengthened

Bisphosphonate link to nonhealing fractures strengthened

Pivotal study of olesoxime in Spinal Muscular Atrophy receives positive interim review

Pivotal study of olesoxime in Spinal Muscular Atrophy receives positive interim review

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Stress and mental illness: an interview with Professor Akira Sawa

Stress and mental illness: an interview with Professor Akira Sawa

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics